{"ticker": {"uuid": "e74a1e8f-7bad-42d9-91d5-2caccd1bec22", "symbol": "CURX", "name": "Curanex Pharmaceuticals Inc Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Cup and Handle", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOcDI4czJVMk5tcHk5S1ZXSXRJbnV6TDFuUnpHYk4tX1NKYjRlQWxYZWdyYlp3SVhBQzNkNW1MOHFtbzBreU5PYk00RlJ0TV8tdWl0Tlk2S3NXMnZVUkRqR2xYUjZrUG5ncENiZjAtTTcyLXFSZWJmc29ubHN6Qk1XWnB2MkZGZk9hMVp0eFh6S2xuemN2NVJzYjZPbWV5cWRqWFQzN1VfTmtfVl9oR0xyY1VLaGpRQjU4VXIxUDJtU2dFdXV0NV9TWg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T16:30:12+00:00", "published_display": "09 Jul 2026 16:30", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Fibonacci Fan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOZVY0OFlGcWFRZjIxakQ3MU5qUW1IbS1qZlBNLWpZZEhmeEg2a2ZPZzd1X2RmSzRSc00tMU1NejNBRE44MW1FVEFFaGJfT1pDNWQ2cHNySmRZb3prNFUxeEthVERNWGdPMXA3Ty1UUDJrWGRQeklwT0hkcEhVSHRIdDh1aXhuZFkxZjJvU0x4LTJJbzB0WmFXdnlFSTJiZHM0QVhhWVVMRzhPZXNyWWNBR2JSUXlaUGxUM0QycXl3M2J3clBTeVhUSmVEcw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals (CURX) Edges Higher as Bulls Defend Key $0.26 Support Level - Factor Rotation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcjdDcXlNeVNSRGIzdXNEaDFaR3NzZWpsZnBWVG4wWTFHWjdaa2RLbU1wdzAtWGZGUXR6YlItbkFLNnJUaFlkcC00R2hfNzNpVXlyQ1ROTDFUOE5uSFFQRWl4Tm5Ob0ZNV1BjYnozeWkxZHc5Yll0ZWRQaWZxeFgyMm15NEZfSjZ0S0lqV3E5RW43R1F6MDhRQlJRUGNWX0dOUXVjU1ZWMVR6NEtodVRMemtEYjljS09ac1dJLXJMRXo?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com", "summary": "This article reports on the filing of Form DEF 14C by Curanex Pharmaceuticals Inc. The document is dated for June 29. The article provides this basic information along with stock performance data for CURX and various market indices.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14c-curanex-pharmaceuticals-inc-for-29-june-93CH-2578411", "source_name": "Investing.com Nigeria", "published_at": "2026-06-29T22:40:23", "published_display": "29 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex (CURX) OKs 5.7M-share incentive plan and 1:10\u20131:50 reverse split", "summary": "Curanex Pharmaceuticals Inc. (CURX) stockholders have approved a 2026 Equity Incentive Plan, reserving up to 5,700,000 shares, and authorized a reverse stock split with a ratio between 1-for-10 and 1-for-50. These actions aim to attract and retain personnel and help regain compli", "url": "https://www.stocktitan.net/sec-filings/CURX/def-14c-curanex-pharmaceuticals-inc-definitive-information-statement-d44361178fae.html", "source_name": "Stock Titan", "published_at": "2026-06-29T14:42:05", "published_display": "29 Jun 2026 14:42", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This article provides financial information for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to revenue (forward). The content highlights the company's financials, news, and community discussions available on TradingView. It indicates ", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:42", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This page provides financial data for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a stub or a placeholder from TradingView, indicating where this financial information would typicall", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:17", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This article provides financial data for Curanex Pharmaceuticals Inc. It focuses on the company's \"Price to book forward\" metric, displayed within the TradingView platform. The content confirms that the market was closed at the time of viewing, showing no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:41:18", "published_display": "25 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Curanex Pharmaceuticals Inc (CURX), focusing on its support, resistance, key indicators, and moving averages. The analysis identifies several sell signals across various technical indicators and moving averages, suggesting a bearish o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T07:40:39", "published_display": "22 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Curanex Pharmaceuticals Inc (CURX), listing its major individual and institutional investors and their respective proportions. It includes data on shareholder types, institutional holdings over several quarters, and recent changes", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/ownership", "source_name": "TradingKey", "published_at": "2026-06-20T01:40:08", "published_display": "20 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This article focuses on the number of shareholders for Curanex Pharmaceuticals Inc, traded on NASDAQ under the symbol CURX. It highlights that the information will be displayed in the \"Period Value Change Change %\" section. The content primarily provides navigation and structural", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-19T12:10:34", "published_display": "19 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M\u2011share plan and 1:10\u20131:50 reverse split", "summary": "Curanex Pharmaceuticals (CURX) has approved a 2026 Equity Incentive Plan, reserving up to 5.7 million shares, and authorized a reverse stock split at a ratio between 1-for-10 and 1-for-50. These corporate actions, approved by majority stockholders via written consent on June 11, ", "url": "https://www.stocktitan.net/sec-filings/CURX/pre-14c-curanex-pharmaceuticals-inc-preliminary-information-statement-bd11371a1f8c.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:53", "published_display": "18 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Institutional Confidence", "summary": "This article provides an overview of Curanex Pharmaceuticals Inc. (CURX) focusing on its institutional confidence and shareholding data. It lists key shareholders including individuals like Liu (Jun) and Liu (Chang), and institutional investors such as Citadel Advisors LLC and Tw", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:41", "published_display": "18 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Curanex Pharmaceuticals Inc (CURX), highlighting its current stock performance, market capitalization, and a lack of disclosed financial forecasting data for EPS, Revenue, Net Profit, and EBIT. It notes that analyst ratings and targe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T18:40:24", "published_display": "18 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Curanex Pharmaceuticals Inc (CURX), focusing on its P/E, P/B, and P/S ratios. The report indicates that relevant data for these valuation metrics have not yet been disclosed by the company. The stock closed at $0.318, experiencing a 5", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T16:09:53", "published_display": "18 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Curanex Pharmaceuticals Inc. (CURX), focusing on its financial health, profitability, and balance sheet. However, the report indicates that relevant financial data for key metrics such as cash and cash equivalents, total assets, revenue, opera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T16:09:53", "published_display": "18 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of dividend payouts and stock splits for Curanex Pharmaceuticals Inc (CURX). It indicates that the company has not distributed any dividends over the past five years and there is no data available for stock splits. The information is pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T09:39:14", "published_display": "17 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX - Curanex Pharmaceuticals Inc Stock Price and Quote", "summary": "Curanex Pharmaceuticals Inc (CURX) stock closed at $0.2652, experiencing a slight decrease of 0.30%. The company has a market capitalization of $7.53M and has been actively reporting on business progress and pipeline expansion, particularly for its Phyto-N candidate in cancer cac", "url": "https://finviz.com/stock?t=CURX", "source_name": "Finviz", "published_at": "2026-05-30T22:10:46", "published_display": "30 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)", "summary": "Wolf Haldenstein Adler Freeman & Herz LLP has launched an investigation into potential securities fraud claims against Curanex Pharmaceuticals Inc. (NASDAQ: CURX) and its officers/directors. The investigation stems from the company's IPO in August 2025, where shares initially ros", "url": "https://www.morningstar.com/news/pr-newswire/20260522ny57963/wolf-haldenstein-adler-freeman-herz-llp-is-investigating-potential-securities-fraud-claims-on-behalf-of-the-shareholders-of-curanex-pharmaceuticals-inc-nasdaq-curx", "source_name": "Morningstar", "published_at": "2026-05-24T07:10:46", "published_display": "24 May 2026 07:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Colitis drug edges toward FDA review as Curanex targets cancer wasting", "summary": "Curanex (CURX) reported significant progress in Q1 2026 for its lead candidate Phyto-N, aiming for a Q4 2026 IND submission to the FDA for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable results, and expanded its pipeline t", "url": "https://www.stocktitan.net/news/CURX/curanex-reports-first-quarter-2026-business-progress-as-phyto-n-4gn2akj3mbmd.html", "source_name": "Stock Titan", "published_at": "2026-05-17T00:09:51", "published_display": "17 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CURX Financials: Income Statement, Balance Sheet & Cash Flow", "summary": "This article provides a detailed financial overview of CURANEX PHARMACEUTICALS INC (CURX) for fiscal year 2025, derived from SEC filings. The company reported a net loss of -$4.2M, with an operating cash outflow of -$10.5M, indicating significant cash burn funded by external fina", "url": "https://www.stocktitan.net/financials/CURX/", "source_name": "Stock Titan", "published_at": "2026-05-15T03:40:23", "published_display": "15 May 2026 03:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/curanex-reports-first-quarter-2026-125300543.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:53:00+00:00", "published_display": "14 May 2026 12:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia", "summary": "Curanex (CURX) provided a Q1 2026 business update, detailing progress for its lead drug candidate, Phyto-N, towards a Q4 2026 Investigational New Drug (IND) submission for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable res", "url": "https://www.stocktitan.net/sec-filings/CURX/8-k-curanex-pharmaceuticals-inc-reports-material-event-c429b1544115.html", "source_name": "Stock Titan", "published_at": "2026-05-14T13:15:51", "published_display": "14 May 2026 13:15", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com", "summary": "Curanex Pharmaceuticals Inc. (NASDAQ:CURX) has completed manufacturing a GMP-compliant batch of Phyto-N and finished toxicology studies for its ulcerative colitis drug candidate. The company plans to submit an Investigational New Drug application to the FDA in Q4 2026 and is also", "url": "https://ca.investing.com/news/stock-market-news/curanex-completes-manufacturing-toxicology-work-for-ulcerative-colitis-drug-93CH-4638421", "source_name": "Investing.com Canada", "published_at": "2026-05-14T13:08:51", "published_display": "14 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline", "summary": "Curanex Pharmaceuticals (CURX) reported a net loss of $3.15 million in Q1 2026, widening from the previous year, primarily due to increased R&D spending on its botanical drug pipeline, Phyto-N. The company has made progress in manufacturing and toxicology studies for Phyto-N, and", "url": "https://www.stocktitan.net/sec-filings/CURX/10-q-curanex-pharmaceuticals-inc-quarterly-earnings-report-5b5e5dc25bcc.html", "source_name": "Stock Titan", "published_at": "2026-05-14T13:08:51", "published_display": "14 May 2026 13:08", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) \u2014 10-Q Summary", "summary": "Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.15M) for Q1 2026, widening from $(137.6K) in Q1 2025, with diluted EPS at $(0.11) against $(0.01) in the prior year. The company completed a GMP pilot-scale batch of Phyto-N and aims for an IND submission in Q4 2026 fo", "url": "https://www.tradingview.com/news/tradingview:04a809e0fbf5d:0-curanex-pharmaceuticals-inc-1q-2026-net-income-3-15m-eps-0-11-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-14T13:08:51", "published_display": "14 May 2026 13:08", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Stock Price", "summary": "This page provides real-time stock information for Curanex Pharmaceuticals Inc (CURX), showing its current trading price, daily change, and market capitalization. It also offers quick links to financial data, discussions, and analysis for the company, and notes that its quotes ar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/comments", "source_name": "TradingKey", "published_at": "2026-05-12T15:10:26", "published_display": "12 May 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance", "summary": "Curanex Pharmaceuticals (NASDAQ: CURX) has been granted an additional 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement for continued listing. The company's stock currently trades at $0.33, down significantly over the past year. Curanex will monitor its ", "url": "https://ng.investing.com/news/sec-filings/curanex-pharmaceuticals-receives-extension-from-nasdaq-to-regain-bid-price-compliance-93CH-2490981", "source_name": "Investing.com Nigeria", "published_at": "2026-05-08T17:10:01", "published_display": "08 May 2026 17:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURANEX PHARMACEUTICALS (CURX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1wdHlCNHMyVWs0cFdXdXZvZk8ybkg5XzlmMVJuUnMyWm55VG5vNzBhbFJiSGZGZEhkN1VUZVNkaktZY2hYaWdvcGYwSTJXMVRHeUh3?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-27T02:51:10+00:00", "published_display": "27 Aug 2025 02:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX Stock Price and Chart \u2014 NASDAQ:CURX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBBaWhURnlqRFJUZDlDNUJrLVU5SmdKTHFlTXRCNS1sM002MXFvckVyeDhjTVAzWWNUeGxaSzJ4VVJvSE43dFE0cXdoM2hrSFJHdVJFMVNmOWdaclps?oc=5", "source_name": "TradingView", "published_at": "2025-08-26T18:47:56+00:00", "published_display": "26 Aug 2025 18:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNcHEwREZaTFNvNUVrdE9HLXllY1hNaS0wX2xMdWprNkhZZF9zZ2VtSXBJVzYzd2tQLWlNZ3BQUFdySVQ5bzdyenROUUFvcGVpdzM0azZGQzl1b2NhRm5vVzNDWXZBcHVmWlJmaUFlWDBkVHRmblhLNndvUEtTWHc4YkF1eXo1T293N29VMjEwMVlqMjROemc?oc=5", "source_name": "Market source", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX IPO News - Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQSG9oZjNzNDVySlRJVnYtQUtGOHRMWDBfRVFSTW81NXJRRS1xT2ZKdzhOOVVZSXo2QnlFUk15dEdNN1FqXzB1b1dHLTA5cXd1ZkQ3RzBULWtoMVBWTk4wbW9yQ1RjcV9tTnlReXA1TnY0cGprODdaQlJvYXQtRkxzTm01VHBoSTh0VlhoZnF0NXI2Rlo0VHJ2b0stUkM1WTd4MG93QkwyQUNRNVF6WW8wSWJqUWZNOVl6UmNmRzBhbXlINEpMZG5NOTZCOA?oc=5", "source_name": "renaissancecapital.com", "published_at": "2024-10-16T07:00:00+00:00", "published_display": "16 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Cup and Handle", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOcDI4czJVMk5tcHk5S1ZXSXRJbnV6TDFuUnpHYk4tX1NKYjRlQWxYZWdyYlp3SVhBQzNkNW1MOHFtbzBreU5PYk00RlJ0TV8tdWl0Tlk2S3NXMnZVUkRqR2xYUjZrUG5ncENiZjAtTTcyLXFSZWJmc29ubHN6Qk1XWnB2MkZGZk9hMVp0eFh6S2xuemN2NVJzYjZPbWV5cWRqWFQzN1VfTmtfVl9oR0xyY1VLaGpRQjU4VXIxUDJtU2dFdXV0NV9TWg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T16:30:12+00:00", "published_display": "09 Jul 2026 16:30", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Fibonacci Fan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOZVY0OFlGcWFRZjIxakQ3MU5qUW1IbS1qZlBNLWpZZEhmeEg2a2ZPZzd1X2RmSzRSc00tMU1NejNBRE44MW1FVEFFaGJfT1pDNWQ2cHNySmRZb3prNFUxeEthVERNWGdPMXA3Ty1UUDJrWGRQeklwT0hkcEhVSHRIdDh1aXhuZFkxZjJvU0x4LTJJbzB0WmFXdnlFSTJiZHM0QVhhWVVMRzhPZXNyWWNBR2JSUXlaUGxUM0QycXl3M2J3clBTeVhUSmVEcw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals (CURX) Edges Higher as Bulls Defend Key $0.26 Support Level - Factor Rotation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcjdDcXlNeVNSRGIzdXNEaDFaR3NzZWpsZnBWVG4wWTFHWjdaa2RLbU1wdzAtWGZGUXR6YlItbkFLNnJUaFlkcC00R2hfNzNpVXlyQ1ROTDFUOE5uSFFQRWl4Tm5Ob0ZNV1BjYnozeWkxZHc5Yll0ZWRQaWZxeFgyMm15NEZfSjZ0S0lqV3E5RW43R1F6MDhRQlJRUGNWX0dOUXVjU1ZWMVR6NEtodVRMemtEYjljS09ac1dJLXJMRXo?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com", "summary": "This article reports on the filing of Form DEF 14C by Curanex Pharmaceuticals Inc. The document is dated for June 29. The article provides this basic information along with stock performance data for CURX and various market indices.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14c-curanex-pharmaceuticals-inc-for-29-june-93CH-2578411", "source_name": "Investing.com Nigeria", "published_at": "2026-06-29T22:40:23", "published_display": "29 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex (CURX) OKs 5.7M-share incentive plan and 1:10\u20131:50 reverse split", "summary": "Curanex Pharmaceuticals Inc. (CURX) stockholders have approved a 2026 Equity Incentive Plan, reserving up to 5,700,000 shares, and authorized a reverse stock split with a ratio between 1-for-10 and 1-for-50. These actions aim to attract and retain personnel and help regain compli", "url": "https://www.stocktitan.net/sec-filings/CURX/def-14c-curanex-pharmaceuticals-inc-definitive-information-statement-d44361178fae.html", "source_name": "Stock Titan", "published_at": "2026-06-29T14:42:05", "published_display": "29 Jun 2026 14:42", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This article provides financial information for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to revenue (forward). The content highlights the company's financials, news, and community discussions available on TradingView. It indicates ", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:42", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This page provides financial data for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a stub or a placeholder from TradingView, indicating where this financial information would typicall", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:17", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This article provides financial data for Curanex Pharmaceuticals Inc. It focuses on the company's \"Price to book forward\" metric, displayed within the TradingView platform. The content confirms that the market was closed at the time of viewing, showing no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:41:18", "published_display": "25 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Curanex Pharmaceuticals Inc (CURX), focusing on its support, resistance, key indicators, and moving averages. The analysis identifies several sell signals across various technical indicators and moving averages, suggesting a bearish o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T07:40:39", "published_display": "22 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Curanex Pharmaceuticals Inc (CURX), listing its major individual and institutional investors and their respective proportions. It includes data on shareholder types, institutional holdings over several quarters, and recent changes", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/ownership", "source_name": "TradingKey", "published_at": "2026-06-20T01:40:08", "published_display": "20 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Curanex Pharmaceuticals Inc \u2013 NASDAQ:CURX", "summary": "This article focuses on the number of shareholders for Curanex Pharmaceuticals Inc, traded on NASDAQ under the symbol CURX. It highlights that the information will be displayed in the \"Period Value Change Change %\" section. The content primarily provides navigation and structural", "url": "https://www.tradingview.com/symbols/NASDAQ-CURX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-19T12:10:34", "published_display": "19 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M\u2011share plan and 1:10\u20131:50 reverse split", "summary": "Curanex Pharmaceuticals (CURX) has approved a 2026 Equity Incentive Plan, reserving up to 5.7 million shares, and authorized a reverse stock split at a ratio between 1-for-10 and 1-for-50. These corporate actions, approved by majority stockholders via written consent on June 11, ", "url": "https://www.stocktitan.net/sec-filings/CURX/pre-14c-curanex-pharmaceuticals-inc-preliminary-information-statement-bd11371a1f8c.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:53", "published_display": "18 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Institutional Confidence", "summary": "This article provides an overview of Curanex Pharmaceuticals Inc. (CURX) focusing on its institutional confidence and shareholding data. It lists key shareholders including individuals like Liu (Jun) and Liu (Chang), and institutional investors such as Citadel Advisors LLC and Tw", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:41", "published_display": "18 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Curanex Pharmaceuticals Inc (CURX), highlighting its current stock performance, market capitalization, and a lack of disclosed financial forecasting data for EPS, Revenue, Net Profit, and EBIT. It notes that analyst ratings and targe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T18:40:24", "published_display": "18 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Curanex Pharmaceuticals Inc (CURX), focusing on its P/E, P/B, and P/S ratios. The report indicates that relevant data for these valuation metrics have not yet been disclosed by the company. The stock closed at $0.318, experiencing a 5", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T16:09:53", "published_display": "18 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Curanex Pharmaceuticals Inc. (CURX), focusing on its financial health, profitability, and balance sheet. However, the report indicates that relevant financial data for key metrics such as cash and cash equivalents, total assets, revenue, opera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T16:09:53", "published_display": "18 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of dividend payouts and stock splits for Curanex Pharmaceuticals Inc (CURX). It indicates that the company has not distributed any dividends over the past five years and there is no data available for stock splits. The information is pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T09:39:14", "published_display": "17 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX - Curanex Pharmaceuticals Inc Stock Price and Quote", "summary": "Curanex Pharmaceuticals Inc (CURX) stock closed at $0.2652, experiencing a slight decrease of 0.30%. The company has a market capitalization of $7.53M and has been actively reporting on business progress and pipeline expansion, particularly for its Phyto-N candidate in cancer cac", "url": "https://finviz.com/stock?t=CURX", "source_name": "Finviz", "published_at": "2026-05-30T22:10:46", "published_display": "30 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)", "summary": "Wolf Haldenstein Adler Freeman & Herz LLP has launched an investigation into potential securities fraud claims against Curanex Pharmaceuticals Inc. (NASDAQ: CURX) and its officers/directors. The investigation stems from the company's IPO in August 2025, where shares initially ros", "url": "https://www.morningstar.com/news/pr-newswire/20260522ny57963/wolf-haldenstein-adler-freeman-herz-llp-is-investigating-potential-securities-fraud-claims-on-behalf-of-the-shareholders-of-curanex-pharmaceuticals-inc-nasdaq-curx", "source_name": "Morningstar", "published_at": "2026-05-24T07:10:46", "published_display": "24 May 2026 07:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Colitis drug edges toward FDA review as Curanex targets cancer wasting", "summary": "Curanex (CURX) reported significant progress in Q1 2026 for its lead candidate Phyto-N, aiming for a Q4 2026 IND submission to the FDA for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable results, and expanded its pipeline t", "url": "https://www.stocktitan.net/news/CURX/curanex-reports-first-quarter-2026-business-progress-as-phyto-n-4gn2akj3mbmd.html", "source_name": "Stock Titan", "published_at": "2026-05-17T00:09:51", "published_display": "17 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX Financials: Income Statement, Balance Sheet & Cash Flow", "summary": "This article provides a detailed financial overview of CURANEX PHARMACEUTICALS INC (CURX) for fiscal year 2025, derived from SEC filings. The company reported a net loss of -$4.2M, with an operating cash outflow of -$10.5M, indicating significant cash burn funded by external fina", "url": "https://www.stocktitan.net/financials/CURX/", "source_name": "Stock Titan", "published_at": "2026-05-15T03:40:23", "published_display": "15 May 2026 03:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/curanex-reports-first-quarter-2026-125300543.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:53:00+00:00", "published_display": "14 May 2026 12:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia", "summary": "Curanex (CURX) provided a Q1 2026 business update, detailing progress for its lead drug candidate, Phyto-N, towards a Q4 2026 Investigational New Drug (IND) submission for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable res", "url": "https://www.stocktitan.net/sec-filings/CURX/8-k-curanex-pharmaceuticals-inc-reports-material-event-c429b1544115.html", "source_name": "Stock Titan", "published_at": "2026-05-14T13:15:51", "published_display": "14 May 2026 13:15", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com", "summary": "Curanex Pharmaceuticals Inc. (NASDAQ:CURX) has completed manufacturing a GMP-compliant batch of Phyto-N and finished toxicology studies for its ulcerative colitis drug candidate. The company plans to submit an Investigational New Drug application to the FDA in Q4 2026 and is also", "url": "https://ca.investing.com/news/stock-market-news/curanex-completes-manufacturing-toxicology-work-for-ulcerative-colitis-drug-93CH-4638421", "source_name": "Investing.com Canada", "published_at": "2026-05-14T13:08:51", "published_display": "14 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline", "summary": "Curanex Pharmaceuticals (CURX) reported a net loss of $3.15 million in Q1 2026, widening from the previous year, primarily due to increased R&D spending on its botanical drug pipeline, Phyto-N. The company has made progress in manufacturing and toxicology studies for Phyto-N, and", "url": "https://www.stocktitan.net/sec-filings/CURX/10-q-curanex-pharmaceuticals-inc-quarterly-earnings-report-5b5e5dc25bcc.html", "source_name": "Stock Titan", "published_at": "2026-05-14T13:08:51", "published_display": "14 May 2026 13:08", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) \u2014 10-Q Summary", "summary": "Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.15M) for Q1 2026, widening from $(137.6K) in Q1 2025, with diluted EPS at $(0.11) against $(0.01) in the prior year. The company completed a GMP pilot-scale batch of Phyto-N and aims for an IND submission in Q4 2026 fo", "url": "https://www.tradingview.com/news/tradingview:04a809e0fbf5d:0-curanex-pharmaceuticals-inc-1q-2026-net-income-3-15m-eps-0-11-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-14T13:08:51", "published_display": "14 May 2026 13:08", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc (CURX) Stock Price", "summary": "This page provides real-time stock information for Curanex Pharmaceuticals Inc (CURX), showing its current trading price, daily change, and market capitalization. It also offers quick links to financial data, discussions, and analysis for the company, and notes that its quotes ar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-curx/comments", "source_name": "TradingKey", "published_at": "2026-05-12T15:10:26", "published_display": "12 May 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance", "summary": "Curanex Pharmaceuticals (NASDAQ: CURX) has been granted an additional 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement for continued listing. The company's stock currently trades at $0.33, down significantly over the past year. Curanex will monitor its ", "url": "https://ng.investing.com/news/sec-filings/curanex-pharmaceuticals-receives-extension-from-nasdaq-to-regain-bid-price-compliance-93CH-2490981", "source_name": "Investing.com Nigeria", "published_at": "2026-05-08T17:10:01", "published_display": "08 May 2026 17:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURANEX PHARMACEUTICALS (CURX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1wdHlCNHMyVWs0cFdXdXZvZk8ybkg5XzlmMVJuUnMyWm55VG5vNzBhbFJiSGZGZEhkN1VUZVNkaktZY2hYaWdvcGYwSTJXMVRHeUh3?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-27T02:51:10+00:00", "published_display": "27 Aug 2025 02:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX Stock Price and Chart \u2014 NASDAQ:CURX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBBaWhURnlqRFJUZDlDNUJrLVU5SmdKTHFlTXRCNS1sM002MXFvckVyeDhjTVAzWWNUeGxaSzJ4VVJvSE43dFE0cXdoM2hrSFJHdVJFMVNmOWdaclps?oc=5", "source_name": "TradingView", "published_at": "2025-08-26T18:47:56+00:00", "published_display": "26 Aug 2025 18:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNcHEwREZaTFNvNUVrdE9HLXllY1hNaS0wX2xMdWprNkhZZF9zZ2VtSXBJVzYzd2tQLWlNZ3BQUFdySVQ5bzdyenROUUFvcGVpdzM0azZGQzl1b2NhRm5vVzNDWXZBcHVmWlJmaUFlWDBkVHRmblhLNndvUEtTWHc4YkF1eXo1T293N29VMjEwMVlqMjROemc?oc=5", "source_name": "Market source", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURX IPO News - Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQSG9oZjNzNDVySlRJVnYtQUtGOHRMWDBfRVFSTW81NXJRRS1xT2ZKdzhOOVVZSXo2QnlFUk15dEdNN1FqXzB1b1dHLTA5cXd1ZkQ3RzBULWtoMVBWTk4wbW9yQ1RjcV9tTnlReXA1TnY0cGprODdaQlJvYXQtRkxzTm01VHBoSTh0VlhoZnF0NXI2Rlo0VHJ2b0stUkM1WTd4MG93QkwyQUNRNVF6WW8wSWJqUWZNOVl6UmNmRzBhbXlINEpMZG5NOTZCOA?oc=5", "source_name": "renaissancecapital.com", "published_at": "2024-10-16T07:00:00+00:00", "published_display": "16 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 73, "total_relevant": 52, "sentiment_summary": {"positive": 11, "negative": 11, "neutral": 30, "score": 48, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.0, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 0.21, "latest_week": "2026-07-17", "one_week_move": -7.7, "four_week_move": -26.5, "twelve_week_move": -52.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.142879, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -76.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.0647, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.7% over one week, -26.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "dars.gov.et", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Barron's", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.7% over one week, -26.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Cup and Handle"}], "updated_at": "2026-07-23T07:55:10.244129+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}